Trial of New Hernia Repair Technique

Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: AbbVie
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The goal of this trial is to assess whether pre-surgical use of the investigation drug, AGN-151607-DP, can enable less invasive hernia repair.

Why do researchers think this study treatment might be promising for ventral hernia?

The investigation drug, AGN-151607-DP, is injected into the muscles near the hernia before surgery to relax them. Researchers believe that making the tissue more pliable will give surgeons a better chance of repairing the hernia without resorting to more invasive techniques like component separation.

Eligibility Criteria

Adults diagnosed with the condition who meet health and safety criteria may be eligible.

Timeline

Screening

Participants are evaluated to confirm eligibility

Up to 4 weeks

Treatment

Participants receive the investigation drug and undergo surgery for their hernia.

16 weeks
Includes regular clinic visits and assessments

Follow-up

Participants are monitored for safety

4 weeks

Hernia Recurrence Follow-up

Phone calls to monitor for hernia recurrence

20 months

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)